Graphical summary. Credit score: Biomaterials (2025). DOI: 10.1016/j.biomaterials.2025.123321
DGIST Division of New Biology Professor Yea Kyungmoo and his analysis crew have developed a next-generation exosome-based drug-delivery know-how to successfully deal with metabolic dysfunction-associated steatohepatitis (MASH), an incurable metabolic illness, in collaboration with Professor Baek Moon-chang of Kyungpook Nationwide College College of Drugs.
The paper is printed within the journal Biomaterials.
MASH is a fancy illness that accompanies varied metabolic illnesses, comparable to weight problems and diabetes, and present therapies are restricted of their effectiveness since they aim solely a single pathological mechanism. Some candidates have both failed scientific trials or are delayed in approval attributable to cardiovascular unintended effects or long-term use issues. Such circumstances reveal the necessity for safer and more practical mixture therapy methods.
To handle these challenges, Professor Yea’s analysis crew achieved the simultaneous engineering of the inside and the floor of extracellular vesicles (exosomes), biologically derived particles that play an important position in delivering indicators between cells, to formulate a bifunctional drug-delivery system that’s particular to the therapy of pathologically complicated MASH.
Exosomes, which carry varied molecules together with proteins, lipids, and genetic supplies, are produced naturally within the physique and are thought of a promising next-generation drug-delivery system as a result of they’ve larger biocompatibility, decrease toxicity, and fewer unintended effects than present lipid-based drug-delivery methods (comparable to COVID-19 vaccines).
The analysis is designed to manage metabolic abnormalities, irritation, and fibrosis concurrently, the primary pathological mechanisms of MASH, by attaching the potent fat-burning protein Fibroblast Development Issue 21 (FGF21) to the floor of the exosomes, and enclosing miRNA-223, which is efficient for regulating irritation and fibrosis. Particularly, the exosomes could also be delivered explicitly to liver tissues, maximizing therapy effectivity.
“This research is the first to demonstrate a novel combination treatment concept utilizing exosomes for MASH, a metabolic disease that is difficult to treat. It sheds light on the potential to overcome the limitations of existing treatment strategies,” Professor Yea mentioned. “We hope to establish a mass production system in the future that will lead to actual drug development.”
Extra info:
Hanchae Cho et al, Engineered extracellular vesicles with floor FGF21 and enclosed miR-223 for treating metabolic dysfunction-associated steatohepatitis, Biomaterials (2025). DOI: 10.1016/j.biomaterials.2025.123321
Offered by
Daegu Gyeongbuk Institute of Science and Know-how
Quotation:
Exosome-based mixture remedy reveals promise for therapy of metabolically difficult illness MASH (2025, April 24)
retrieved 24 April 2025
from https://medicalxpress.com/information/2025-04-exosome-based-combination-therapy-treatment.html
This doc is topic to copyright. Other than any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.
